<div id="readability-page-1"><div><p>CONMED (CNMD) opened 2026 with Q1 revenue of US$317.0 million and basic EPS of US$0.45, setting the tone for how margins are holding up after a year of shifting profitability. The company has seen quarterly revenue move from US$321.3 million and EPS of US$0.19 in Q1 2025 to US$317.0 million and EPS of US$0.45 in Q1 2026, while trailing 12 month revenue sits at about US$1.4 billion and EPS at US$1.77. This puts the focus squarely on how efficiently that top line is being converted into profit.</p> <p>See our full analysis for CONMED.</p><p>With the headline numbers on the table, the next step is to see how this earnings profile lines up with the big narratives around growth, margins and profit quality that investors have been watching.</p> <p>See what the community is saying about CONMED</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d83997f0-5375-4f45-a2db-2a0ab2633599/chart/revenue-and-expenses-breakdown/query-ZGF0ZT0yMDI2LTA1LTAx?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d83997f0-5375-4f45-a2db-2a0ab2633599/chart/revenue-and-expenses-breakdown/query-ZGF0ZT0yMDI2LTA1LTAx"/><figcaption>NYSE:CNMD Revenue &amp; Expenses Breakdown as at May 2026</figcaption></figure> <h2>Margins Under Pressure, Despite US$1.4b Trailing Sales</h2> <ul> <li>Over the last 12 months, CONMED generated about US$1.4b in revenue with net income of US$54.8 million, which works out to a 4% net margin compared with 9% a year earlier.</li> <li>Consensus narrative expects operational improvements and higher-margin products to support better profitability over time. The current 4% margin and the earlier 9% level highlight the gap that needs to be closed.     <ul> <li>Analysts are cited as looking for earnings growth of around 30.8% per year over the next three years, compared with revenue growth of about 3.8% per year. This implies a focus on margins doing more of the heavy lifting than sales growth.</li> <li>The trailing margin step down, combined with this forecasted earnings ramp, gives you a clear point to compare future reports against, especially if costs or pricing move differently from what the narrative assumes.</li> </ul> </li> </ul> <h2>TTM Earnings Growth vs 4% Margin Squeeze</h2> <ul> <li>Over the past five years, earnings grew at about 25.7% per year, yet the latest trailing 12 month net profit margin sits at 4%, down from 9% in the prior 12 month period.</li> <li>Bulls argue that supply chain fixes and cost savings can support stronger profitability, and the historical 25.7% earnings growth rate is often used as a reference point. However, the recent 4% margin keeps the bullish case heavily dependent on future execution.     <ul> <li>The bullish narrative points to at least US$20 million in annualized savings from operational efficiencies and expects margins to rise over time, which contrasts with the current drop from 9% to 4% in the trailing numbers.</li> <li>For a beginner investor, this means the bullish story leans on management turning cost actions and product mix into a margin profile that looks closer to the historical trend than to the latest 12 month snapshot.</li> </ul> </li> </ul><p> Sustained margin improvement is central to what optimistic investors are betting on, so if you want to see how that full upside case is laid out, check out the <strong>🐂 CONMED Bull Case</strong>. </p><h2>Low Margin, High Debt Keep Bears Engaged</h2> <ul> <li>The trailing 12 month period includes a US$26.0 million one off loss and a net margin of 4%, and the company is described as having a high level of debt on the balance sheet.</li> <li>Bears highlight that slower forecast revenue growth of about 3.8% per year, a compressed 4% margin, the US$26.0 million one off loss, and elevated leverage together leave less room for error if costs stay high or procedure volumes soften.     <ul> <li>The cautious narrative leans on rising healthcare cost controls, tariff and supply chain risks, and pressure on hospital budgets, which would all make it harder to improve on a 4% margin starting point.</li> <li>When reading future filings, you can compare any movement in margins or debt levels against this baseline to see whether the more cautious story or the optimistic one is getting more support from the numbers.</li> </ul> </li> </ul><p> Skeptical investors are watching whether these balance sheet and margin issues ease or persist, and you can see that full cautious case in the <strong>🐻 CONMED Bear Case</strong>. </p><h2>Next Steps</h2> <p>To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for CONMED on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.</p> <p>With sentiment clearly split between the bull and bear cases, it helps to move fast, review the numbers yourself, and decide where you stand, starting with 3 key rewards and 3 important warning signs.</p> <h2>Explore Alternatives</h2> <p>CONMED's recent 4% net margin, one off US$26.0 million loss, and high debt levels leave limited room for error if conditions tighten.</p> <p>If that mix of thin margins and leverage feels uncomfortable, you might want to focus on companies with stronger cushions by starting with the solid balance sheet and fundamentals stocks screener (44 results).</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><div><p>• Dividend Powerhouses (3%+ Yield)<br/>• Undervalued Small Caps with Insider Buying<br/>• High growth Tech and AI Companies</p><p>Or build your own from over 50 metrics.</p></div><p>Explore Now for Free</p></div></div></div>

CNMD

<p>CONMED (CNMD) reported Q1 2026 revenue of $317 million and EPS of $0.45, reflecting a decline in net margin to 4% from 9% a year prior. Analysts forecast earnings growth of 30.8% annually, relying on operational improvements to enhance profitability. However, concerns arise from a $26 million one-off loss and high debt levels, which could hinder margin recovery. Investors are divided, with bulls optimistic about future margin improvements and bears cautious due to potential revenue growth challenges and rising costs.</p>

CONMED (CNMD) Q1 Margin Compression To 4% Tests Bullish Earnings Growth Narrative